|
|
|
Abstract Objective To explore the impact of gene 13(Atg13) on promoting chemotherapy resistance in triple-negative breast cancer (TNBC) cells. Methods We developed a doxorubicin-resistant MDA-MB-231/Dox cell lines using intermittent application of doxorubicin (Dox). MDA-MB-231/Dox was determined by the drug-sensitive assay and the apoptosis assay (TUNEL staining).The expression of LC3A and LC3B in TNBC cells (MDA-MB-231 and MDA-MB-231/Dox) was detected by Western Blot (WB). The number of LC3B fluorescence spots in the cells was quantified by immunofluorescence. Recombinant plasmid sh-Atg13 was transfected into MDA-MB-231/Dox by liposome， then stable cells (referred to as MDA-MB-231/Dox+sh-Atg13) were obtained by puromycin screening (PM). The Atg13 expression level in MDA-MB-231/Dox+sh-Atg13 and empty plasmid MDA-MB-231/Dox+control plasmid by WB. Changes in autophagy activity were determined by the level of LC3A， LC3B expression and the number of LC3B fluorescent spots. Drug sensitivity of each cell line to Dox was also examined. Results Dox-resistant TNBC cell line MDA-MB-231/Dox were successfully established in vitro. The results showed that the level of basal autophagy in drug-resistant cells was significantly higher than that in sensitive cells MDA-MB-231(P<0.05). After inhibiting the expression of Atg13 gene by recombinant interference plasmid sh-Atg13， the protein expression of autophagy marker LC3B in drug-resistant cells MDA-MB-231/Dox was significantly decreased (P<0.05)， the drug sensitivity of MDA-MB-231/Dox cells to Dox was increased (IC50 value was significant， P<0.05). Conclusion In TNBC cell MDA-MB-231， Atg13 increased chemotherapy resistance by inducing autophagy were determined.
|
|
|
|
|
|
1.Woolston C. Breast cancer:4 big questions. Nature. 2015;527(7578):S120.
2.Jiao Q， Wu A， Shao G， et al.The latest progress in research on triple negative breast cancer (TNBC): risk factors， possible therapeutic targets and prognostic markers.J Thorac Dis. 2014;6(9):1329-1335.
3.McCann KE， Hurvitz SA， McAndrew N. Advances in targeted therapies for triple-negative breast cancer.Drugs. 2019;79(11):1217-1230.
4.Pusztai L， Foldi J， Dhawan A，et al. Changing frameworks in treatment sequencing of triple-negative and HER2-positive， early-stage breast cancers.Lancet Oncol. 2019;20(7):e390-e396.
5.Planes-Laine G， Rochigneux P， Bertucci F，et al. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. A literature review.Cancers (Basel). 2019;11(7):E1033.
6.Novikov O，Wang Z，Stanford EA，et al.An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-/PR-/Her2-human breast cancer cells. Mol Pharmacol. 2016;90(5):674-688.
7.Aydinlik S，Erkisa M，Cevatemre B，et al.Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line. Biochim Biophys Acta Gen Subj. 2017;1861(2):49-57.
8.Woo SM， Kim AJ， Choi YK， et al. Synergistic effect of SH003 and doxorubicin in triple-negative breast cancer.Phytother Res. 2016;30(11):1817-1823.
9.Angelini A， Conti P， Ciofani G， et al. Modulation of multidrug resistance P-glycoprotein activity by antiemetic compounds in human doxorubicin-resistant sarcoma cells (MES-SA/Dx-5): implications on cancer therapy. J Biol Regul Homeost Agents. 2013;27(4):1029-1037.
10.Pan YZ， Wang X， Bai H， et al. Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin.Genet Mol Res. 2015;14(2):5621-5629.
11.Kochel TJ， Reader JC， Ma X， et al. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2(PGE2) and contributes to metastasis in basal/triple negative breast cancer.Oncotarget. 2017;8(4):6540-6554.
12.Zhang L， Shamaladevi N， Jayaprakasha GK， et al. Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice.Oncotarget. 2015;6(18):16379-16395.
13.Brand JS， Hedayati E， Humphreys K， et al.Chemotherapy， genetic susceptibility， and risk of venous thromboembolism in breast cancer patients.Clin Cancer Res. 2016;22(21):5249-5255.
14.Xu SW， Law BY， Mok SW， et al. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. Int J Oncol. 2016;49(4):1576-1588.
15.Wang W， Kang H， Zhao Y， et al. Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J Clin Endocrinol Metab. 2017;102(2):634-643.
16.Zhong JT， Yu J， Wang HJ， et al. Effects of endoplasmic reticulum stress on the autophagy， apoptosis， and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway. Tumour Biol. 2017;39(5):1010428317697562.
17.Cheong JW， Kim Y， Eom JI， et al. Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance. Mol Med Rep. 2016;13(4):3433-3440.
18.Guo B， Tam A， Santi SA， et al. Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. BMC Cancer. 2016;16(1):762.
19.Ladoire S， Enot D， Senovilla L， et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;12(5):864-875.
20.Zhao H， Yang M， Zhao J， et al. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol. 2013;30(1):475. |
|
|
